Purpose: Neoadjuvant chemotherapy has been shown to improve survival in locally advanced gastric cancer, but it is associated with significant toxicity. Sarcopenia and sarcopenic obesity have been studied in several types of cancers and have been reported to be associated with higher chemotherapy toxicity and morbi-mortality. The aim of this study was to assess the prevalence of sarcopenia/sarcopenic obesity in patients with gastric cancer, as well as its association with chemotherapy toxicity and long-term outcomes.
Materials And Methods: A retrospective analysis was performed using an academic cancer center patient cohort diagnosed with locally advanced gastric cancer between January 2012 and December 2014 and treated with neoadjuvant chemotherapy. We analyzed body composition (skeletal muscle and visceral fat index) in axial computed tomography images.
Results: A total of 48 patients met the inclusion criteria. The mean age was 68±10 years, and 33 patients (69%) were men. Dose-limiting toxicity was observed in 22 patients (46%), and treatment was terminated early owing to toxicity in 17 patients (35%). Median follow-up was 17 months. Sarcopenia and sarcopenic obesity were found at diagnosis in 23% and 10% of patients, respectively. We observed an association between termination of chemotherapy and both sarcopenia (P=0.069) and sarcopenic obesity (P=0.004). On multivariate analysis, the odds of treatment termination were higher in patients with sarcopenia (odds ratio=4.23; P=0.050). Patients with sarcopenic obesity showed lower overall survival (median survival of 6 months [95% confidence interval {CI}=3.9-8.5] vs. 25 months [95% CI=20.2-38.2]; log-rank test P=0.000).
Conclusions: Sarcopenia and sarcopenic obesity were associated with early termination of neoadjuvant chemotherapy in patients with gastric cancer; additionally, sarcopenic obesity was associated with poor survival.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362836 | PMC |
| http://dx.doi.org/10.5230/jgc.2017.17.e8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of triglyceride glucose-related obesity indices with sarcopenia among U.S. adults: a cross-sectional study from the National Health and Nutrition Examination Survey.
Sci Rep
January 2025
Department of Cardiology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, China.
The triglyceride glucose (TyG) index-related obesity indices have been proposed as reliable indicators of insulin resistance. This study aims to investigate the association between TyG index-related obesity indices and sarcopenia as well as their potential as a tool for screening sarcopenic patients. A cross-sectional study was conducted involving 7,161 participants aged 18 and above from the National Health and Nutrition Examination Survey.
View Article and Find Full Text PDFCorrelation and predictive value of novel anthropometric indicators with adult sarcopenia and sarcopenia obesity.
Sci Rep
December 2024
Beijing Sport University, Beijing, China.
The present study leverages the comprehensive data from the National Health and Nutrition Examination Survey (NHANES) to examine the Influencing factors of sarcopenia (SA) and sarcopenic obesity (SO). The investigation is designed to a non-invasive, cost-effective, and convenient method that is applicable to the adult population, enabling the accurate and simultaneous detection of risks associated with SA and SO. Furthermore, this research will evaluate the critical values of effective anthropometric indicators, providing early warning for risk management in self-health care and offering valuable insights for subsequent research and clinical practice.
View Article and Find Full Text PDFSarcopenic obesity is significantly associated with poorer overall survival after liver transplantation: a systematic review and meta-analysis.
Front Nutr
December 2024
Department of Critical Care Medicine, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Background: Sarcopenia has been shown to worsen survival after liver transplantation. However, it remains unclear whether coexisting sarcopenia and obesity, so-called sarcopenic obesity (SO), may also synergistically increase their adverse effects. This meta-analysis aimed to evaluate whether pre-transplant SO independently predicts survival in this population.
View Article and Find Full Text PDFBridging the Gap: Supplements Strategies from Experimental Research to Clinical Applications in Sarcopenic Obesity.
Curr Issues Mol Biol
November 2024
Department of Biochemistry, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Obesity causes fat accumulation, and sarcopenia causes loss of muscle mass and strength; together, they worsen insulin resistance and accelerate muscle decline, creating a harmful cycle. Some supplements, along with physical exercise, could be remedies for sarcopenic obesity (SO). In this review, we aim to draw a comparison between supplements studied in experimental research and those evaluated in clinical studies for SO.
View Article and Find Full Text PDFImpact of sarcopenic obesity on postoperative outcomes in patients with oesophago-gastric cancer: A systematic review and meta-analysis.
World J Surg
December 2024
Department of Gastroenterological Surgery, Cancer Institute Ariake Hospital, Tokyo, Japan.
Background: We elucidated the influence of sarcopenic obesity on postoperative outcomes in patients with oesophago-gastric cancer.
Methods: We conducted a systematic search on MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, the World Health Organization International Clinical Trials Platform Search Portal, and ClinicalTrials.gov to identify observational studies published from their inception to September 26, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!